ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹3,771 Cr (+15.8% YoY) and net profit of ₹301.3 Cr (+6747.7% YoY) for Q4 FY26.
Glenmark Pharmaceuticals approved FY26 audited financial results and recommended a 250% dividend. The Board's approval highlights the company's annual performance and shareholder reward plans.
Glenmark USA settled US antitrust litigation with state attorneys general for ₹281.47 Crore. Payable over five years, the settlement avoids uncertainty without admitting any liability.
Glenmark's subsidiary announced ISB 2301, a first-in-class multispecific activator targeting solid tumors. Clinical studies are planned for 2027 following IND submission later this year.
Glenmark Pharmaceuticals scheduled a board meeting for May 29, 2026. Directors will approve FY26 financial results and consider recommending a dividend to shareholders.
Glenmark launched Vancomycin Hydrochloride for Injection in the U.S. market. The product targets a ₹363.84 Crore market, strengthening the company's injectable portfolio and presence.
Glenmark Pharmaceuticals Limited confirmed it is not classified as a Large Corporate as per SEBI criteria for the financial year. Consequently, the company is not required to submit incremental debt disclosures under the circular framework. The filing reports zero outstanding borrowings as of the reporting date.
Glenmark Pharmaceuticals received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg. The product targets a market with annual sales of approximately ₹544.64 Crore ($59.2 million). This approval strengthens Glenmark's women's healthcare portfolio in the U.S. market.
Glenmark Pharmaceuticals Ltd reported net profit of ₹403 Cr (+15.8% YoY) for Q3 FY26.